Coeur Mining's Q4 Revenue Surge Masks Fragile Execution and High Valuation

What happened

Coeur Mining reported a 121% revenue surge in Q4'25 to $674.7 million, driven by higher gold and silver prices and strong output growth across key operations. However, this positive momentum is already priced into the stock, with valuations at elevated levels of 38.0x EV/EBITDA and 29.7x P/E, leaving no margin of safety according to the DeepValue report. The investment thesis hinges on fragile execution at the Rochester expansion, cost normalization at Las Chispas amid purchase price allocation noise, and timely closure of the New Gold acquisition by H1'26. Insider selling in August-September 2025, including clustered open-market sales by multiple executives, adds a cautionary signal about potential overvaluation or lack of confidence. Key upcoming catalysts, such as FY2025 results on February 18, 2026, and Investment Canada Act approval by May 31, 2026, remain critical to de-risking the high-expectations narrative.

Implication

The Q4 revenue surge confirms operational momentum but fails to address core investment risks, such as Rochester's fragile expansion economics and Las Chispas integration challenges. With valuations at 38.0x EV/EBITDA, the stock prices in perfect execution of multiple ramps and the New Gold deal, offering limited upside without hard de-risking. Insider selling in 2025 suggests potential overvaluation, aligning with the DeepValue report's 'WAIT' rating and highlighting a crowded, momentum-driven market sentiment. Investors should wait for clearer signals from upcoming catalysts, like Investment Canada Act approval and 2026 guidance, before increasing exposure, as current levels lack cushion for delays or cost misses. Focusing on these forward-looking events, rather than backward-looking sales data, is essential to avoid downside in a stock with no margin of safety.

Thesis delta

The strong Q4 performance supports the momentum narrative but does not shift the underlying thesis, which remains contingent on future execution and regulatory approval. No material change is warranted; the 'WAIT' rating persists, as the revenue surge does not de-risk Rochester's fragility, Las Chispas normalization, or the New Gold timeline. Investors should continue to prioritize the upcoming FY2025 results and M&A milestones over historical sales figures.